| Code | CSB-RA023984MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Exlinkibart, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing T cell proliferation, survival, and cytotoxic function. Upon binding to its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that amplify immune responses. This pathway has significant implications in cancer immunotherapy, autoimmune diseases, and viral infections, where modulation of T cell activation can influence disease outcomes.
Exlinkibart represents an investigational agonistic antibody designed to stimulate TNFRSF9 signaling and enhance anti-tumor immunity. This biosimilar antibody provides researchers with a valuable tool for investigating TNFRSF9-mediated immune activation mechanisms, exploring combination immunotherapy strategies, and studying T cell costimulation in various disease models. The antibody supports preclinical research into immune checkpoint modulation and the development of novel therapeutic approaches targeting the TNFRSF9 pathway.
There are currently no reviews for this product.